Farallon Capital Management
$16.9B 13F equity value
186 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Farallon Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| RVMD | REVOLUTION MEDICINES INC | 13,550,796 | $2.5B | 15.0% |
| EA | ELECTRONIC ARTS INC | 7,919,500 | $1.6B | 9.6% |
| BBIO | BRIDGEBIO PHARMA INC | 10,743,063 | $800M | 4.7% |
| PTGX | PROTAGONIST THERAPEUTICS INC | 6,348,906 | $778M | 4.6% |
| EXEL | EXELIXIS INC | 13,468,010 | $733M | 4.3% |
| LQDA | LIQUIDIA CORPORATION | 8,365,038 | $667M | 3.9% |
| AMZN | AMAZON COM INC | 2,632,994 | $628M | 3.7% |
| LNTH | LANTHEUS HLDGS INC | 5,583,479 | $619M | 3.7% |
| NTRA | NATERA INC | 2,218,366 | $602M | 3.6% |
| UNH | UNITEDHEALTH GROUP INC | 1,270,532 | $528M | 3.1% |
Track Farallon Capital Management's 13F portfolio: $16.9B in reported holdings, 186 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}